Intellectual Property Generally. As between the parties, the Intellectual Property in the Development Deliverables and Goods are comprised entirely of Apple Technology and/or Supplier Technology as set forth in this Agreement.
Intellectual Property Generally. (i) With respect to Intellectual Property owned by such Grantor, such Grantor (either itself or through licensees) shall, except as could not reasonably be expected to result in a Material Adverse Effect, (i) continue to use each Trademark material to Grantor’s business in order to maintain such Trademark in full force and effect with respect to each class of goods for which such Trademark is currently used, free from any claim of abandonment for non-use, (ii) maintain consistent with past practice the quality of products and services offered under such Trademark, (iii) use such Trademark with the appropriate notice of registration and all other notices and legends required by Applicable Law, (iv) not adopt or use any xxxx that is confusingly similar to or a colorable imitation of such Trademark unless the Secured Party shall obtain a perfected security interest in such xxxx pursuant to this Agreement and (v) not (and use commercially reasonable efforts to not permit any licensee or sublicensee thereof to) do any act or knowingly omit to do any act whereby such Trademark (or any goodwill associated therewith) may become destroyed, invalidated, impaired or harmed in any way. Grantor (either itself or through licensees) shall not do any act, or omit to do any act, whereby any Patent owned by such Grantor that is material to Grantor’s business may become forfeited, abandoned or dedicated to the public. Grantor (either itself or through licensees) (x) shall not (and shall not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby any portion of any Copyright that is material to Grantor’s business may become invalidated or otherwise impaired and (y) shall not (either itself or through licensees) do any act whereby any portion of any Copyright that is material to Grantor’s business may fall into the public domain. Grantor (either itself or through licensees) shall not do any act, or omit to do any act, whereby any trade secret may become publicly available or otherwise unprotectable. Grantor (either itself or through licensees) shall not do any act that knowingly uses any Intellectual Property to infringe, misappropriate, or violate the intellectual property rights of any other Person.
Intellectual Property Generally. Upon request of the Administrative Agent, execute and deliver any and all agreements, instruments, documents, and papers as the Administrative Agent may reasonably request to evidence the Administrative Agent’s security interest in the Intellectual Property and the general intangibles relating thereto including, without limitation, the goodwill of the Obligors and their Subsidiaries relating thereto or represented thereby (or such other Intellectual Property or the general intangibles relating thereto or represented thereby as the Administrative Agent may reasonably request).
Intellectual Property Generally. Upon request of the Secured Party, execute and deliver any and all agreements, instruments, documents, and papers as the Secured Party may reasonably request to evidence the Secured Party’s security interest in the Intellectual Property and the general intangibles relating thereto including, without limitation, the goodwill of the Obligors and their Subsidiaries relating thereto or represented thereby (or such other Intellectual Property or the general intangibles relating thereto or represented thereby as the Secured Party may reasonably request).
Intellectual Property Generally. Except as disclosed on Schedules 4.10(a):
Intellectual Property Generally. Each Party shall be solely responsible for the costs of filing, prosecution and maintenance of patents and patent applications on its own [ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Intellectual Property Generally. Each Party shall be solely responsible for the costs of filing, prosecution and maintenance of patents and patent applications on its own Inventions. Either Party shall give the other Party written notice, as promptly as practicable, of all Inventions which can reasonably be deemed to constitute improvements or other modifications of a Product or processes or technology used under this Agreement. Except as otherwise expressly provided herein, nothing contained in this CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE REVANCE THERAPEUTICS, INC., HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT REVANCE THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL. Agreement shall be construed or interpreted, either expressly or by implication, estoppel or otherwise, as a grant, transfer or other conveyance by either Party to the other of any right, title, license or other interest of any kind in any of its Intellectual Property.
Intellectual Property Generally. Except for items not material to the business of the Company, all intellectual property, trademarks, service marks, trade dress, logos and trade names and registrations and applications for registration thereof, and all renewals and extensions thereof, together with the good will associated therewith; all license agreements relating to patents and/or inventions, and all patents and patent applications or their equivalent and copyrights and registrations and for registration thereof, and trade secrets and confidential business information and know-how, owned or licensed to Company which are of any value or importance to its business or which it is authorized to use in the production or marketing of any products now produced or proposed to be product or marketed (collectively the "Intellectual Property") are listed or identified in Exhibit 2.1(dd)(ii), and to the extent indicated therein have been duly registered in, filed in or issued by the United States Patent and Trademark Office or other appropriate governmental office. Except as set forth in Exhibit 2.1(dd)(ii), Company is the sole person entitled to use the Intellectual Property, free and clear of any claims or demands of any other person; Company does not require the consent of any other person to use any of the Intellectual Property; Company does not know of any encumbrances thereon; Company pays no licensing fee, royalty or other payment to any other person with respect to any of the Intellectual Property or the use thereof; and Company's right to use and transfer any and all of the Intellectual Property is perpetual and unrestricted. The Company has no knowledge of any claims or demands of any other person or entity pertaining to any of the Intellectual Property and has no knowledge of any proceedings which have been instituted or are pending or threatened which challenge the rights of Company with respect thereto, or that any of the Intellectual Property infringes or is being infringed upon by others or is subject to any outstanding order, decree, judgment or stipulation.
Intellectual Property Generally. (a) The Corporation (i) exclusively owns and has independently developed or acquired or (ii) has the valid right or license to Exploit, all Corporation IP. The Corporation IP is sufficient for the conduct of the Corporation’s business as currently conducted and as currently proposed to be conducted. To the Knowledge of the Corporation, all Corporation Intellectual Property Rights are valid, subsisting, and enforceable. The Corporation has the sole and exclusive right to bring a Claim or suit against any third party’s infringement of the Corporation Intellectual Property Rights and to retain for itself any damages recovered in any such action.
Intellectual Property Generally. Except as otherwise expressly set forth herein or in a separate written agreement between the Parties, all information received from RELYPSA in connection with the performance of this Agreement or obtained as a result of LANXESS’s performance of this Agreement, including the information contained in the Master Batch Record or Batch records, results, data, reports, final reports, laboratory work sheets, information about API, Bulk Intermediates or Bulk Drug, Manufacturing Records and other Manufacturing information (“RELYPSA Information”), shall be the sole and exclusive property of RELYPSA; provided however, RELYPSA Information shall not include LANXESS Intellectual Property, except for Know-How that is included in Discoveries. RELYPSA shall be free to disclose and use RELYPSA Information for any purpose, including the manufacture (directly or through a Third Party), use, sale, commercialization or other exploitation of the Product; provided further, that RELYPSA shall not disclose any LANXESS Intellectual Property (including Know-How) in any Batch record, the Master Batch Record or any other Manufacturing Record to any MFA, Bulk Intermediate, API, or Bulk Drug manufacturer that is a Competitor of LANXESS, without the prior written consent of LANXESS.
